Literature DB >> 1829078

Prophylaxis, cost and effectiveness of therapy of infections caused by gram-positive organisms in neutropenic children.

G S Schaison1, F C Decroly.   

Abstract

Gram-positive infections are being reported with increasing frequency in children with haematological malignancies. Staphylococcus epidermidis, once considered a non-pathogenic skin contaminant, is emerging as a major cause of severe infection. However, in infants Gram-negative septicaemias are more frequent than in older children. A teicoplanin and ceftriaxone combination was assessed for use as empirical therapy of febrile episodes in neutropenic children with acute leukaemias. Of 47 patients, fever was of unknown origin in 21, and documented in 26 with 28 strains isolated; 19 Gram-positive (all sensitive to teicoplanin) and nine Gram-negative. Within 48 h, 41 patients became afebrile and the pathogen was cleared if initially present. Mean duration of treatment was 16 days. Febrile relapse occurred in 24 patients with eight documented superinfections. The need for prophylactic cover against Gram-positive organisms at the time of intravenous catheter insertion is questionable. We studied 71 patients who were randomly allocated to receive teicoplanin when the central line was inserted and if febrile, with added ceftriaxone and amikacin (arm A) or the tri-antibiotic regimen when fever occurred (arm B). In arm A a febrile episode occurred after ten days in 34/35 patients with only one Gram-positive organism isolated. In arm B a febrile episode occurred in all 36 patients after five days and ten Gram-positive strains were isolated. Those patients in arm A also received fluconazole. Amphotericin B was administered in cases of failure or relapses in both groups.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1829078     DOI: 10.1093/jac/27.suppl_b.61

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  8 in total

Review 1.  A survey of the use of teicoplanin in patients with haematological malignancies and solid tumours.

Authors:  J M Davies
Journal:  Infection       Date:  1998 Nov-Dec       Impact factor: 3.553

2.  Ceftriaxone. A pharmacoeconomic evaluation of its use in the treatment of serious infections.

Authors:  R Davis; H M Bryson
Journal:  Pharmacoeconomics       Date:  1994-09       Impact factor: 4.981

3.  In vitro activity of vancomycin and teicoplanin against Staphylococcus aureus and Staphylococcus epidermidis colonizing catheters.

Authors:  A Kropec; J Huebner; M Wursthorn; F D Daschner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-07       Impact factor: 3.267

Review 4.  Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy.

Authors:  Anat Gafter-Gvili; Abigail Fraser; Mical Paul; Liat Vidal; Theresa A Lawrie; Marianne D van de Wetering; Leontien C M Kremer; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2012-01-18

5.  Detection of bacteraemia in patients with fever and neutropenia using 16S rRNA gene amplification by polymerase chain reaction.

Authors:  B E Ley; C J Linton; D M Bennett; H Jalal; A B Foot; M R Millar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-04       Impact factor: 3.267

6.  Ceftriaxone/Amikacin vs Ceftazidime/Amikacin as Empirical Therapy for Fever in Patients with Haematological Malignancy and Severe Granulocytopenia: Clinical and Economic Outcomes.

Authors:  F Rossini; P Pioltelli; S Bolis; L Borin; I Casaroli; E Lanzi; P Maffè; M Parma; P Tripputi; E M Pogliani
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

Review 7.  Teicoplanin. A reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  R N Brogden; D H Peters
Journal:  Drugs       Date:  1994-05       Impact factor: 9.546

Review 8.  Safety of fluconazole in paediatrics: a systematic review.

Authors:  Oluwaseun Egunsola; Abiodun Adefurin; Apostolos Fakis; Evelyne Jacqz-Aigrain; Imti Choonara; Helen Sammons
Journal:  Eur J Clin Pharmacol       Date:  2013-01-17       Impact factor: 2.953

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.